Article

Live Broadcast to Explore a Treatment Option for EGFR Exon20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer

In an upcoming live broadcast, Dr. Mark Socinski and Dr. Erminia Massarelli will discuss EGFR Exon20 insertion-positive non-small cell lung cancer and take a deeper look at current guideline-recommended testing. They will also talk about the safety and efficacy of a new option in patients previously treated with platinum-based chemotherapy. Additionally, they will discuss the implications of the data through a live question and answer session.

To obtain expert perspective and learn about how these results may affect your patients and your practice, watch the live broadcast on November 16th at 7PM ET or 9PM ET or November 17th at 12PM ET. To register for the event, visit https://studio.mjhassoc.com/reach/takedaonclivebroadcast.

USO-NON-0332 10/21

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.